Swiss-based biotechnology company Kuros Biosciences intends to raise funds through the rights offering of shares of its common stock to raise between Sfr20.15m ($20.68m) and Sfr25m ($25.66m).
The shares will be offered in the price range from Sfr12.5 ($12.83) to Sfr15.5 ($15.91) a share.
Go deeper with GlobalData
The company has concurrently announced a public offering of shares, proceeds from which are intended to be used for the commercialisation of the company’s products, MagnetOS and Neuroseal.
Austrian drug delivery company Suda has signed a binding memorandum of understanding (MoU) to acquire Aluztra Bio’s global intellectual property relating to Anagrelide, an anti-cancer agent that reduces the level of platelets and its potentially non-toxic analogues.
Aluztra Bio is a biotechnology company based in the UK.
See Also:
US-based biotechnology company ProLynx has partnered with Daiichi Sankyo, a Japanese pharmaceutical company.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe partnership is intended at evaluating the company’s drug delivery linker technology in the eye.
US-based biopharmaceutical company Celsion Corporation intends to raise $5.5m in gross proceeds through the private placement of two million shares of its common stock or pre-funded warrants in lieu thereof.
Priced at $2.75 a share, the placement is expected to be subscribed to by institutional investors.
The proceeds are intended to be used for general corporate purposes.
